SAN FRANCISCO, Feb. 25, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX) today announced the pricing of an underwritten public offering of 2,362,205 shares of its common stock at a price to the public of $1.27 per share. Gross proceeds to CollabRx from this offering are approximately $3,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by CollabRx. CollabRx has granted the underwriter a 45-day option to purchase up to an additional 354,330 shares of common stock to cover over-allotments, if any. The offering is expected to close on March 3, 2015, subject to customary closing conditions.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
This offering is being made pursuant to an effective shelf registration statement (No. 333-193019) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that CollabRx has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about CollabRx and such offering.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to this offering may be obtained, when available, from Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org.
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties, including statements regarding our expectations with respect to the application of the net proceeds from the offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and CollabRx cautions investors not to place undue reliance on the forward-looking statements contained in this release. Risks and uncertainties relating to CollabRx and this offering can be found in the “Risk Factors” section of the prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Thomas R. Mika
President & Chief Executive Officer
Dian Griesel Int’l.
Laura Radocaj- media
Cheryl Schneider- investors